BTK and mantle cell lymphoma: The combination of venetoclax plus the Bruton’s tyrosine kinase BTK inhibitor ibrutinib (given until progression) was evaluated in a pivotal single-arm phase 2 study in patients with relapsed or refractory MCL (23 out of 24 patients) or previously untreated MCL with contraindication for cytotoxic chemotherapy (1 out of 24 patients).